ABPI update on the pharmaceutical industry and coronavirus

16 March 2020 Posted in News by Press Office

As a critical part of the health care community in the UK, the pharmaceutical industry wants to play the biggest possible role in the response to this outbreak.

As part of the health community, pharmaceutical companies want to play as big a role as possible in the response to COVID–19.  Richard Torbett

The ABPI has launched a new webpage 'Responding to COVID-19' which provides the industry's view on the outbreak and brings together guidance for member companies.

Richard Torbett, Chief Executive of the ABPI, said:

“As part of the health community, pharmaceutical companies want to play as big a role as possible in the response to COVID–19. 

“All companies should make appropriate contingency plans that may be required for further stages of the government's action plan and be prepared for the situation to last many months.

“We are working closely with the Department of Health and the NHS on how our members can best support the Government as plans evolve and adapt to the changing situation.

Check out our new page on responding to COVID-19 here.

TAGS
  • COVID 19

Last modified: 20 September 2023

Last reviewed: 20 September 2023

The ABPI exists to make the UK the best place in the world to research, develop and use new medicines. We represent companies of all sizes who invest in discovering the medicines of the future. 

Our members supply cutting edge treatments that improve and save the lives of millions of people. We work in partnership with Government and the NHS so patients can get new treatments faster and the NHS can plan how much it spends on medicines. Every day, we partner with organisations in the life sciences community and beyond to transform lives across the UK.

Media enquiries

+44 (0) 20 7747 7147​​